Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

被引：0

作者：

Mittelman, Moshe ^{[1
,7
]}

Platzbecker, Uwe ^{[2
]}

Grosicki, Sebastian ^{[3
]}

Lawniczek, Tomasz ^{[4
]}

Zhu, Zewen ^{[5
]}

Selleslag, Dominik ^{[6
]}

机构：

[1] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel

[2] Univ Hosp Leipzig, Med Clin & Polyclin 1, Hematol & Cellular Therapy, Leipzig, Germany

[3] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

[4] Novartis Pharm AG, Basel, Switzerland

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] AZ Sint Jan Brugge Oostende AV, Dept Hematol, Brugge, Belgium

[7] Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-6423906 Tel Aviv, Israel

来源：

ACTA HAEMATOLOGICA | 2023年 / 146卷 / 05期

关键词：

Advanced myelodysplastic syndrome; Acute myeloid leukemia; Eltrombopag; Thrombocytopenia; PLACEBO; BLIND; RISK; INTERMEDIATE; ROMIPLOSTIM; MDS;

D O I：

10.1159/000531146

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ASPIRE, a three-part, international, phase 2 trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia and grade 4 thrombocytopenia (<25 x 10(9) platelets/L). Approximately 30-65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no conclusions could be made regarding long-term efficacy (non-randomized design, no placebo control), and survival rates may simply reflect advanced disease. Long-term safety was consistent with the double-blind phase and contrasted with earlier SUPPORT study findings in higher-risk patients, suggesting that eltrombopag may have a role in treating thrombocytopenia in patients with low-/intermediate-risk myelodysplastic syndrome.

引用

页码：373 / 378

页数：6

共 50 条

[21] Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study
Pasi, J.
Perry, D.
Mahlangu, J.
Konkle, B.
Rangarajan, S.
Brown, S. A.
Hanabusa, H.
Jackson, S.
Pabinger-Fasching, I.
Cristiano, L. M.
Li, X.
Pierce, G. F.
Allen, G.
HAEMOPHILIA, 2015, 21 : 52 - 53
[22] PLACEBO-CONTROLLED, RANDOMIZED, PHASE I/II TRIAL OF THE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG IN THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA
Platzbecker, U.
Wong, R.
Verma, A.
Abboud, C.
Araujo, S.
Chiou, T.
Feigert, J.
Yeh, S.
Goetze, K.
Gorin, N.
Greenberg, P.
Kambhampati, S.
Kim, Y.
Lee, J.
Lyons, R.
Ruggeri, M.
Santini, V.
Cheng, G.
Jang, J.
Chen, C.
Dougherty, S.
Mannino, F.
Kamel, Y.
Chan, G.
Arning, M.
Stone, N.
Giagounidis, A.
HAEMATOLOGICA, 2013, 98 : 455 - 455
[23] Interim Analysis Of The ASPIRE Study Evaluating Long-term Safety And Efficacy Of Recombinant Factor VIII FC (RFVIIIFC) In Children With Severe Haemophilia A
Nolan, B.
Young, G.
Mahlangu, J.
Liesner, R.
Pasi, J.
Cristiano, L. M.
Li, X.
Pierce, G. F.
Allen, G.
HAEMOPHILIA, 2015, 21 : 58 - 59
[24] Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND
Saleh, Mansoor N.
Cheng, Gregory
Bussel, James B.
Burgess, Paul
Bakshi, Kalpana
Brainsky, Andres
Bailey, Christine K.
BLOOD, 2012, 120 (21)
[25] BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study
Ljung, Rolf
Chan, Anthony K. C.
Ahuja, Sanjay P.
Mancuso, Maria Elisa
Marquez, Jose Francisco Cabre
Volk, Florian
Blanchette, Victor
Kerlin, Bryce A.
Trakymiene, Sonata Saulyte
Glosli, Heidi
Kenet, Gili
EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (03) : 556 - 565
[26] Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
Platzbecker, Uwe
Wong, Raymond S. M.
Verma, Amit
Abboud, Camille
Araujo, Sergio
Chiou, Tzeon-Jye
Feigert, John
Yeh, Su-Peng
Goetze, Katharina
Gorin, Norbert-Claude
Greenberg, Peter
Kambhampati, Suman
Kim, Yoo-Jin
Lee, Je-Hwan
Lyons, Roger
Ruggeri, Marco
Santini, Valeria
Cheng, Gregory
Jang, Jun Ho
Chen, Chien-Yuan
Johnson, Brendan
Bennett, John
Mannino, Frank
Kamel, Yasser Mostafa
Stone, Nicole
Dougherty, Souria
Chan, Geoffrey
Giagounidis, Aristoteles
LANCET HAEMATOLOGY, 2015, 2 (10): : E417 - E426
[27] Eltrombopag in thrombocytopenic patients with advanced myclodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: A phase I/II study
Wroblewski, S.
Shi, W.
Mudd, P., Jr.
Aivado, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[28] LONG TERM FOLLOW UP OF PATIENTS OVER 60 YEARS TREATED WITH INTENSIVE CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
Blum, S.
Schuler, E.
Hildebrandt, B.
Kuendgen, A.
Giagounidis, A.
Kobbe, G.
Haas, R.
Aul, C.
Gattermann, N.
Germing, U.
HAEMATOLOGICA, 2017, 102 : 385 - 385
[29] Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study
Yang, Lin
Shi, Lei
Fu, Qiang
Xiong, Huihua
Zhang, Mengxian
Yu, Shiying
ONCOLOGY LETTERS, 2012, 3 (04) : 935 - 939
[30] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
Banerji, A.
Hao, J.
Yu, M.
Bernstein, J.
Johnston, D.
Riedl, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21

← 1 2 3 4 5 →